A case of cardiogenic shock caused by capecitabine treatment

被引：2

作者：

To, Andrew C. Y. ^{[1
]}

Looi, Khang Li ^{[1
]}

Damianovich, Dragan ^{[1
]}

Taylor, Graeme B. ^{[1
]}

Sidebotham, David ^{[1
]}

White, Harvey D. ^{[1
]}

机构：

[1] Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland 1023, New Zealand

来源：

NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE | 2008年 / 5卷 / 11期

关键词：

5-fluorouracil; capecitabine; cardiogenic shock; cardiomyopathy; cardiotoxicity;

D O I：

10.1038/ncpcardio1352

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background A 52-year-old woman underwent successful resection of stage IIB primary mucinous adenocarcinoma of the appendix and was started on capecitabine chemotherapy. Five days into the first course, after initially experiencing diarrhea, nausea, vomiting and a transient episode of retrosternal chest pain radiating to the left scapula, she presented to the emergency department with cardiogenic shock. Investigations Electrocardiography, transthoracic echocardiography, laboratory investigation of cardiac biomarkers, coronary angiography and endomyocardial biopsy. Diagnosis Capecitabine-induced cardiogenic shock. Management Supportive treatment with dopamine, milrinone, norepinephrine (noradrenaline) and levosimendan.

引用

页码：725 / 729

页数：5

共 16 条

[1]

Alter P., 2006, Cardiovascular & Hematological Agents in Medicinal Chemistry, V4, P1, DOI 10.2174/187152506775268785

[2] Cardiotoxicity of the antiproliferative compound fluorouracil [J].

Becker, K ;

Erckenbrecht, JF ;

Häussinger, D ;

Frieling, T .

DRUGS, 1999, 57 (04) :475-484

[3] Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy [J].

Cardinale, D ;

Sandri, MT ;

Colombo, A ;

Colombo, N ;

Boeri, M ;

Lamantia, G ;

Civelli, M ;

Peccatori, F ;

Martinelli, G ;

Fiorentini, C ;

Cipolla, CM .

CIRCULATION, 2004, 109 (22) :2749-2754

[4] Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition [J].

Cardinale, Daniela ;

Colombo, Alessandro ;

Sandri, Maria T. ;

Lamantia, Giuseppina ;

Colombo, Nicola ;

Civelli, Maurizio ;

Martinelli, Giovanni ;

Veglia, Fabrizio ;

Fiorentini, Cesare ;

Cipolla, Carlo M. .

CIRCULATION, 2006, 114 (23) :2474-2481

[5] Docus on research: Herceptin and the heart - A molecular modifier of cardiac failure [J].

Chien, KR .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (08) :789-790

[6] Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study [J].

Hoff, PM ;

Ansari, R ;

Batist, G ;

Cox, J ;

Kocha, W ;

Kuperminc, M ;

Maroun, J ;

Walde, D ;

Weaver, C ;

Harrison, E ;

Burger, HU ;

Osterwalder, B ;

Wang, AO ;

Wong, R .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2282-2292

[7] Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine [J].

Jensen, SA ;

Sorensen, JB .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (04) :487-493

[8]

Merkel S, 2001, CANCER, V92, P1435, DOI 10.1002/1097-0142(20010915)92:6<1435::AID-CNCR1467>3.0.CO

[9]

2-N

[10]

Meyer CC, 1997, PHARMACOTHERAPY, V17, P729

← 1 2 →